ERAMET (ER7.DE) Stock Fundamental Analysis
FRA:ER7 - FR0000131757 - Common Stock
51.15 EUR
-1.7 (-3.22%)
Overall ER7 gets a fundamental rating of 3 out of 10. We evaluated ER7 against 37 industry peers in the Metals & Mining industry. ER7 may be in some trouble as it scores bad on both profitability and health. ER7 is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ER7 has reported negative net income.
ER7 had a negative operating cash flow in the past year.
Of the past 5 years ER7 4 years were profitable.
Of the past 5 years ER7 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.58%, ER7 is doing worse than 67.57% of the companies in the same industry.
Looking at the Return On Equity, with a value of -9.29%, ER7 is doing worse than 72.97% of the companies in the same industry.
ER7's Return On Invested Capital of 0.80% is on the low side compared to the rest of the industry. ER7 is outperformed by 67.57% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ER7 is in line with the industry average of 8.00%.
The 3 year average ROIC (7.29%) for ER7 is well above the current ROIC(0.80%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.58% | ||
| ROE | -9.29% | ||
| ROIC | 0.8% |
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
1.3 Margins
ER7's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 1.91%, ER7 is not doing good in the industry: 67.57% of the companies in the same industry are doing better.
ER7's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 68.15%, ER7 belongs to the best of the industry, outperforming 91.89% of the companies in the same industry.
ER7's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.91% | ||
| PM (TTM) | N/A | ||
| GM | 68.15% |
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ER7 is destroying value.
ER7 has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ER7 has more shares outstanding
Compared to 1 year ago, ER7 has an improved debt to assets ratio.
2.2 Solvency
ER7 has an Altman-Z score of 1.08. This is a bad value and indicates that ER7 is not financially healthy and even has some risk of bankruptcy.
ER7 has a worse Altman-Z score (1.08) than 72.97% of its industry peers.
ER7 has a Debt/Equity ratio of 2.03. This is a high value indicating a heavy dependency on external financing.
ER7 has a Debt to Equity ratio of 2.03. This is amonst the worse of the industry: ER7 underperforms 89.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.08 |
ROIC/WACC0.09
WACC9.14%
2.3 Liquidity
ER7 has a Current Ratio of 1.54. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.54, ER7 is not doing good in the industry: 67.57% of the companies in the same industry are doing better.
A Quick Ratio of 1.06 indicates that ER7 should not have too much problems paying its short term obligations.
ER7 has a Quick ratio (1.06) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
The earnings per share for ER7 have decreased strongly by -221.18% in the last year.
ER7 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -64.00% yearly.
Looking at the last year, ER7 shows a decrease in Revenue. The Revenue has decreased by -6.91% in the last year.
Measured over the past years, ER7 shows a decrease in Revenue. The Revenue has been decreasing by -4.39% on average per year.
EPS 1Y (TTM)-221.18%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
3.2 Future
ER7 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.34% yearly.
The Revenue is expected to grow by 8.02% on average over the next years. This is quite good.
EPS Next Y-274.73%
EPS Next 2Y-2.62%
EPS Next 3Y29.34%
EPS Next 5YN/A
Revenue Next Year6.82%
Revenue Next 2Y7.82%
Revenue Next 3Y8.02%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ER7. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 12.85, which indicates a correct valuation of ER7.
ER7's Price/Forward Earnings is on the same level as the industry average.
ER7 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.63, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.85 |
4.2 Price Multiples
ER7's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. ER7 is more expensive than 72.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 14.51 |
4.3 Compensation for Growth
ER7's earnings are expected to grow with 29.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.62%
EPS Next 3Y29.34%
5. Dividend
5.1 Amount
ER7 has a Yearly Dividend Yield of 2.62%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 3.16, ER7 pays a bit more dividend than its industry peers.
ER7's Dividend Yield is comparable with the S&P500 average which is at 2.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.62% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
ER7 has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-44.33%
EPS Next 2Y-2.62%
EPS Next 3Y29.34%
FRA:ER7 (8/29/2025, 7:00:00 PM)
51.15
-1.7 (-3.22%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)
Earnings (Next)
Inst Owners11.85%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.47B
Analysts75.56
Price Target57.36 (12.14%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.62% |
Yearly Dividend1.51
Dividend Growth(5Y)N/A
DP-44.33%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.99%
PT rev (3m)-10.97%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-513.67%
EPS NY rev (3m)-513.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)1.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.85 | ||
| P/S | 0.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.41 | ||
| P/tB | 2.72 | ||
| EV/EBITDA | 14.51 |
EPS(TTM)-3.44
EYN/A
EPS(NY)3.98
Fwd EY7.78%
FCF(TTM)-25.76
FCFYN/A
OCF(TTM)-4.59
OCFYN/A
SpS100.31
BVpS36.3
TBVpS18.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.58% | ||
| ROE | -9.29% | ||
| ROCE | 1.16% | ||
| ROIC | 0.8% | ||
| ROICexc | 0.95% | ||
| ROICexgc | 1.09% | ||
| OM | 1.91% | ||
| PM (TTM) | N/A | ||
| GM | 68.15% | ||
| FCFM | N/A |
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ROICexc(3y)10.98%
ROICexc(5y)11.38%
ROICexgc(3y)12.91%
ROICexgc(5y)13.43%
ROCE(3y)10.76%
ROCE(5y)11.32%
ROICexcg growth 3Y-56.22%
ROICexcg growth 5Y-25.38%
ROICexc growth 3Y-55.33%
ROICexc growth 5Y-24.94%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
F-Score2
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 10.29 | ||
| Cap/Depr | 403.31% | ||
| Cap/Sales | 21.11% | ||
| Interest Coverage | 0.34 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 1.08 |
F-Score2
WACC9.14%
ROIC/WACC0.09
Cap/Depr(3y)260.42%
Cap/Depr(5y)209.27%
Cap/Sales(3y)18.57%
Cap/Sales(5y)15.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-221.18%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
EPS Next Y-274.73%
EPS Next 2Y-2.62%
EPS Next 3Y29.34%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
Revenue Next Year6.82%
Revenue Next 2Y7.82%
Revenue Next 3Y8.02%
Revenue Next 5YN/A
EBIT growth 1Y-51.75%
EBIT growth 3Y-50.34%
EBIT growth 5Y-22.39%
EBIT Next Year104.71%
EBIT Next 3Y37.27%
EBIT Next 5YN/A
FCF growth 1Y-850%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.46%
OCF growth 3YN/A
OCF growth 5YN/A